Details about Paul Vincent Grootendorst

Access statistics for papers by Paul Vincent Grootendorst.

Last updated 2024-02-06. Update your information in the RePEc Author Service.

Short-id: pgr189

Working Papers

2020

1. An Empirical Examination of the Patented Medicine Prices Review Board Price Control Amendments on Drug Launches in Canada
   Working Papers, Canadian Centre for Health Economics

2017

2. Does rising income inequality affect mortality rates in advanced economies?
   Economics Discussion Papers, Kiel Institute for the World Economy (IfW Kiel) View citations (1)
   See also Journal Article Does rising income inequality affect mortality rates in advanced economies?, Economics - The Open-Access, Open-Assessment E-Journal (2007-2020), Kiel Institute for the World Economy (IfW Kiel) (2017) View citations (1) (2017)

2015

3. Intellectual Property Protection And Drug Plan Coverage: Evidence From Ontario
   Working Papers, Canadian Centre for Health Economics View citations (1)

2011

4. Economic Instruments for Obesity Prevention: Results of a Scoping Review and Modified Delphi Survey
   Monash Economics Working Papers, Monash University, Department of Economics View citations (3)

2010

5. New Approaches to Rewarding Pharmaceutical Innovation
   Levine's Bibliography, UCLA Department of Economics View citations (3)

2009

6. How should we support pharmaceutical innovation?
   Social and Economic Dimensions of an Aging Population Research Papers, McMaster University View citations (3)
7. Patents, Public-Private Partnerships or Prizes – How should we support pharmaceutical innovation?
   Social and Economic Dimensions of an Aging Population Research Papers, McMaster University

2007

8. A review of instrumental variables estimation in the applied health sciences
   Social and Economic Dimensions of an Aging Population Research Papers, McMaster University View citations (6)
9. Effects of 'Authorized-Generics' on Canadian Drug Prices
   Social and Economic Dimensions of an Aging Population Research Papers, McMaster University View citations (1)
10. The life expectancy gains from pharmaceutical drugs: a critical appraisal of the literature
    Social and Economic Dimensions of an Aging Population Research Papers, McMaster University View citations (2)

2004

11. The Impact of Differential Cost Sharing of Non-Steroidal Anti-Inflammatory Agents on the Use and Costs of Analgesic Drugs
    Social and Economic Dimensions of an Aging Population Research Papers, McMaster University View citations (6)

2003

12. National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?
    Social and Economic Dimensions of an Aging Population Research Papers, McMaster University
    Also in Quantitative Studies in Economics and Population Research Reports, McMaster University (2003)
    See also Journal Article National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?, Canadian Public Policy, University of Toronto Press (2005) (2005)
13. Out-of-Pocket Prescription Drug Expenditures and Public Prescription Drug Programs
    IZA Discussion Papers, Institute of Labor Economics (IZA) View citations (1)
    Also in Quantitative Studies in Economics and Population Research Reports, McMaster University (2002)
    Social and Economic Dimensions of an Aging Population Research Papers, McMaster University (2002)

2002

14. Do Drug Plans Matter? Effects of Drug Plan Eligibility on Drug Use Among the Elderly, Social Assistance Recipients and the General Population
    Quantitative Studies in Economics and Population Research Reports, McMaster University View citations (5)
    Also in Social and Economic Dimensions of an Aging Population Research Papers, McMaster University (2002) View citations (6)
15. The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume I: Summary
    Quantitative Studies in Economics and Population Research Reports, McMaster University View citations (2)
    Also in Social and Economic Dimensions of an Aging Population Research Papers, McMaster University (2002) View citations (1)
16. The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report
    Quantitative Studies in Economics and Population Research Reports, McMaster University
    Also in Social and Economic Dimensions of an Aging Population Research Papers, McMaster University (2002)

2001

17. An Empirical Analysis of Milk Addiction
    Working Papers, Department of Economics, University of Calgary View citations (2)
    See also Journal Article An empirical analysis of milk addiction, Journal of Health Economics, Elsevier (2004) View citations (54) (2004)
18. International Experience With Pharmaceutical Policy: Common Challenges and Lessons for Canada
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada View citations (2)

2000

19. The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada
    Quantitative Studies in Economics and Population Research Reports, McMaster University View citations (1)
    Also in CEPR Discussion Papers, Centre for Economic Policy Research, Research School of Economics, Australian National University (2000)
    Social and Economic Dimensions of an Aging Population Research Papers, McMaster University (2000)
    See also Journal Article The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada, Journal of Health Economics, Elsevier (2002) View citations (16) (2002)

1999

20. Beneficiary Cost Sharing Under Canadian Provincial Prescription Drug Benefit Programs: History and Assessment
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada View citations (13)
21. Evidence of Construct Validity for Stoke and Arthritis in a Population Health Survey
    Department of Economics Working Papers, McMaster University View citations (2)
22. Health Utilities Index Mark 3: Evidence of Construct Validity for Stroke and Arthritis in a Population Health Survey
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada View citations (9)

1998

23. Variance in Pharmacare Coverage Across Canada
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada View citations (1)

1996

24. Financial Incentives to Dispense Low-Cost Drugs: A Case Study of British Columbia Pharmacare
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada View citations (2)

1995

25. On Becoming 65 in Ontario: Effects of Provincial Drug Plan Eligibility on Utilization of Prescription Medicines
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada View citations (3)

1994

26. Does It Matter Whom and How You Ask? Inter and Intra-rater Agreement in the Ontario Health Survey
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada View citations (9)

1993

27. Results of an Investigation into the Integrity of the Ontario Health Survey
    Centre for Health Economics and Policy Analysis Working Paper Series, Centre for Health Economics and Policy Analysis (CHEPA), McMaster University, Hamilton, Canada

Journal Articles

2022

1. The effect of patented drug price on the share of new medicines across OECD countries
   Health Policy, 2022, 126, (8), 795-801 View citations (2)

2017

2. Differences in Incremental Cost-Effectiveness Ratios for Common Versus Rare Conditions: A Case from Oncology
   PharmacoEconomics - Open, 2017, 1, (3), 167-173
3. Does rising income inequality affect mortality rates in advanced economies?
   Economics - The Open-Access, Open-Assessment E-Journal (2007-2020), 2017, 11, 1-23 View citations (1)
   See also Working Paper Does rising income inequality affect mortality rates in advanced economies?, Economics Discussion Papers (2017) View citations (1) (2017)

2015

4. Newton's First Law as Applied to Pharmacies: Why Entry Order Matters for Generics
   International Journal of the Economics of Business, 2015, 22, (2), 201-217 View citations (2)

2014

5. Do downturns cause desperation? The effect of economic conditions on suicide rates in Canada
   Applied Economics, 2014, 46, (10), 1081-1092 View citations (4)

2011

6. The cost of drug development: A systematic review
   Health Policy, 2011, 100, (1), 4-17 View citations (22)

2007

7. The effects of coxib formulary restrictions on analgesic use and cost: Regional evidence from Canada
   Health Policy, 2007, 84, (1), 1-13

2006

8. A re‐examination of the impact of reference pricing on anti‐hypertensive drug plan expenditures in British Columbia
   Health Economics, 2006, 15, (7), 735-742 View citations (9)

2005

9. Distributional effects of `general population' prescription drug programs in Canada
   Canadian Journal of Economics, 2005, 38, (1), 128-148 View citations (11)
   Also in Canadian Journal of Economics/Revue canadienne d'économique, 2005, 38, (1), 128-148 (2005) View citations (3)
10. Estimating the price elasticity of expenditure for prescription drugs in the presence of non‐linear price schedules: an illustration from Quebec, Canada
    Health Economics, 2005, 14, (9), 909-923 View citations (31)
11. National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?
    Canadian Public Policy, 2005, 31, (4), 341-358
    See also Working Paper National Catastrophic Drug Insurance Revisited: Who Would Benefit from Senator Kirby's Recommendations?, Social and Economic Dimensions of an Aging Population Research Papers (2003) (2003)

2004

12. An empirical analysis of milk addiction
    Journal of Health Economics, 2004, 23, (6), 1117-1133 View citations (54)
    See also Working Paper An Empirical Analysis of Milk Addiction, Working Papers (2001) View citations (2) (2001)

2002

13. The effects of drug subsidies on out-of-pocket prescription drug expenditures by seniors: regional evidence from Canada
    Journal of Health Economics, 2002, 21, (5), 805-826 View citations (16)
    See also Working Paper The Effects of Drug Subsidies on Out-of Pocket Prescription Drug Expenditures by Seniors: Regional Evidence from Canada, Quantitative Studies in Economics and Population Research Reports (2000) View citations (1) (2000)

2001

14. On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective
    Health Policy, 2001, 55, (2), 97-109 View citations (2)

1997

15. Health care policy evaluation using longitudinal insurance claims data: An application of the Panel Tobit estimator
    Health Economics, 1997, 6, (4), 365-382 View citations (16)

Chapters

2012

1. Prescription Drug Insurance and Reimbursement
   Chapter 11 in The Elgar Companion to Health Economics, Second Edition, 2012 View citations (1)
   Also in Chapter 11 in The Elgar Companion to Health Economics, 2006 (2006)